Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of beclomethasone dipropionate delivered by breath-actuated or metered-dose inhaler for persistent asthma.

Author: AmarNiran J, KerwinEdward M, LiJiang, MossMark H, SmallCalvin J

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This phase III study found that beclomethasone dipropionate hydrofluoroalkane breath-actuated inhaler (BAI) at 320 and 640 μg/day, and metered-dose inhaler (MDI) at 640 μg/day, demonstrated clinical benefits for patients with persistent asthma. The safety profiles of BAI 320 and 640 μg/day were comparable with that of the MDI.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Breath-actuated inhalers (BAI) have been developed to simplify the delivery of inhaled medication. OBJECTIVE: To evaluate the safety and efficacy of beclomethasone dipropionate hydrofluoroalkane BAI and metered-dose inhaler (MDI) versus placebo in patients who previously used a mid- to ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2500/aap.2016.37.3983

データ提供：米国国立医学図書館（NLM）

Beclomethasone Dipropionate: A Breath-Activated Solution for Persistent Asthma

Asthma, a chronic respiratory condition, requires constant vigilance and effective treatment. This study explores the efficacy and safety of beclomethasone dipropionate delivered by breath-activated inhalers (BAI) compared to traditional metered-dose inhalers (MDI) in patients with persistent asthma. The authors conduct a phase III clinical trial to assess the effectiveness of both BAI and MDI formulations in controlling asthma symptoms and improving lung function.

A Breath of Fresh Air for Asthma Treatment

The study demonstrates the clinical benefits of both BAI and MDI formulations of beclomethasone dipropionate in managing persistent asthma. The authors report significant improvements in lung function, asthma control, and symptom severity in patients receiving active treatment compared to placebo. The safety profiles of BAI and MDI formulations appear comparable, suggesting that BAI could offer a convenient and effective alternative for patients with persistent asthma.

Navigating the Asthma Landscape

This research, like a compass guiding us through the challenges of asthma management, highlights the potential of BAI as a valuable tool for improving patient outcomes. The findings suggest that BAI could offer a more convenient and effective delivery method for beclomethasone dipropionate, potentially improving patient adherence to medication and enhancing asthma control. It's crucial to consult with healthcare professionals to determine the most appropriate treatment approach for your individual needs.

Dr.Camel's Conclusion

This study, like a refreshing breeze in the desert of asthma, underscores the potential of BAI as a convenient and effective option for managing persistent asthma. The findings suggest that BAI could offer a more patient-friendly approach to delivering beclomethasone dipropionate, promoting better adherence and enhancing asthma control. This research is a testament to the ongoing evolution of asthma treatments, offering new hope for improving patient outcomes.

Date :
  1. Date Completed 2017-03-10
  2. Date Revised 2017-08-17
Further Info :

Pubmed ID

27510595

DOI: Digital Object Identifier

10.2500/aap.2016.37.3983

Related Literature

Article Analysis
・Effects of beclomethasone oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.